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thermore to illustrate its application in the area of os-
teoporosis, where economic evaluations predominantly
take the form of decision-analytical models.
METHODS: A systematic review involving electronic da-
tabases and hand-searches was conducted of full economic
evaluations of interventions in osteoporosis. The included
studies were assessed using a checklist based on the Co-
chrane Collaboration handbook for systematic reviews.
The six main items of the checklist included the (i) specifi-
cation of the research question (ii) comprehensiveness of
the literature review (iii) critical appraisal of studies (iv)
relevance of the data extraction (v) appropriateness of the
analysis and (vi) handling of uncertainty.
RESULTS: 18 studies met the criteria for inclusion (UK 
6, US  7, Australia  2). 16 studies considered hormone
replacement therapy, 3 calcitonin, 2 calcium and 2 bisphos-
phonates. It was found that 28% satisfied 4 or more of the
six main criteria. It was also found that only 33% studies
did a comprehensive literature review; primary studies
were predominantly epidemiological, but only 4 appraised
the quality of the observational data.
CONCLUSION: These results demonstrate methodological
weaknesses in the process of including data in osteoporosis
models. Quality checklists for economic models should
therefore emphasise the identification, retrieval, extraction
and pooling methods for the clinical outcome data. Further
there should be increased transparency in the reporting of
economic models to assist in model quality assessment and
validation. Future research should focus on the impact of bi-
ased data selection on cost effectiveness ratios.
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OBJECTIVES: To study the cost of illness for patients
newly diagnosed with benign prostate hyperplasia (BPH)
in different scenarios.
METHODS: Published data provide the clinical results of
current relevant management for new BPH patients: al-
pha-blockers (AB), watchful waiting (WW) or surgery (S).
Based on these data, we simulated the history of patients
with moderate BPH in a state transitional model, starting
with one of the three treatment options. The model covers
10 periods of 1 year, and simulates real life treatment
switches (e.g., from WW to AB, from one AB to another,
from WW to S, etc. . .). Ten centres were asked to provide
data on medical management at different states, based on
their local audits. Resulting direct medical costs were cal-
culated from the health care insurance perspective and ap-
plied into the model. Costs were discounted at 3%. The
model was validated by comparison of predicted with ob-
served surgery rates from a National hospital database (68
hospitals).
RESULTS: Patients starting on WW have the lowest cumu-
lative costs (3,750 Euro, SD  3,767 ), followed by patients
starting with AB: 4,559 Euro for tamsulosin (SD  1,702)
and 4,744 Euro for terazosin (SD  1,651). Introducing AB
as second choice after WW has caused an observed reduc-
tion in S rates in Belgium. If AB would not exist, the in-
creased and earlier use of surgery would lead to a predicted
extra cost per patient of 60 Euro per year during the first 5
years, and in the long run to a break-even situation. The
model overestimated observed surgical rates by 4.5%.
CONCLUSIONS: The introduction of AB seems to lead
to a delay of surgery in BPH patients, with short term sav-
ings and long term break-even. The real life short-term
savings may be lower than the predicted, since the model
overestimates the surgical rates.
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Migraine has an estimated prevalence of 11.4% in Italy
and is associated with significant morbidity.
OBJECTIVE: To estimate resource consumption (RC) and
costs related to migraine in Italy.
METHODS: This was an observational, multicenter sur-
vey of a patient population attended by general practitio-
ners (GPs). Patients who visited their GPs on five consecu-
tive days of two different weeks were asked if they suffered
from headache. Patients with headache were asked to par-
ticipate in the study if their condition met the International
Headache Society criteria for migraine. Migraineurs re-
ceived a diary in which to record attacks and treatments.
During subsequent GP visits, patients were administered an
RC questionnaire on medical services and lost workdays
due to migraine. Assessment of RC was from the commu-
nity perspective. Values were assigned according to official
sources, and average annual costs in Euro (E) per patient
were calculated.
RESULTS: During the first trimester of 1996, 902 GPs col-
lected data on 71,588 evaluable patients. Prevalence of mi-
graine in the sample was 11.6%. Health care resources (di-
rect costs) accounted for 52.4% of the total annual cost,
while lost workdays (indirect costs) accounted for the re-
maining 47.6%. The total annual cost per migraneur was
E599. Direct costs included: medical consultations E49
(8% of total); tests E63 (11%); drugs E43 (7%); and hospi-
talizations E157 (26%). A total of 2.8 workdays per pa-
tient were lost annually due to migraine. Extrapolated to
the total (active) population in Italy, this corresponds to
15,016,870 lost workdays, amounting to over E1.5 billion
in indirect costs per year. As Italian migraneurs exceed
5,440,000, the total annual cost of migraine in Italy is over
E3.2 billion.
